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Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiother-
apy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were
encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomog-
raphy and fluoroscopy images throughout the treatment course and on computed tomography images
during follow-up (0–38 months). Marker volume reduction was seen until 9 months after treatment, after
which no further marker breakdown was found. No post-treatment migration or marker related compli-
cations were found.
 2018 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Image guidance has improved the precision of lung cancer
radiotherapy (RT) [1,2]. Radio-opaque markers (fiducial markers)
can be used as surrogates for the target position when image con-
trast is poor [3]. Thoracic implantation of fiducial markers is
described in several studies [4–15]. Depending on tumour location,
the markers can be inserted percutaneously [10–12] or endoscop-
ically [13–15]. Percutaneous implantation carries a higher risk of
pneumothorax [7,10–12], while markers placed endoscopically in
the bronchi can dislodge and migrate [6].
Liquid fiducial markers can be injected using standard endo-
scopic equipment, and allows for larger flexibility in marker size
and performing several marker injections in an uninterrupted pro-
cedure. Previous studies of liquid markers in thoracic RT haveshowed limitations in radio-opacity [16,17] or have limited data
on stability throughout the RT course [18]. Furthermore, data on
the post-treatment stability (migration) of fiducial markers in
lungcancer patients has only been sparsely reported [6,19].
BioXmark (Nanovi Radiotherapy A/S, Lyngby, Denmark) is a liq-
uid fiducial marker that changes viscosity after injection. It consists
of sucrose acetate isobutyrate (SAIB), an iodinated analogue of SAIB
and ethanol. Upon injection into soft tissue, the ethanol starts
diffusing out of the matrix, causing an increase in marker viscosity,
resulting in a sticky gel-like marker after a few hours. The marker
degrades into non-toxic compounds by hydrolysis over an
expected period of years. Pre-clinical phantom and animal studies
have demonstrated the marker to be safe and fully biocompatible
as well as having good contrast in ultrasound, 2D and 3D kV
X-ray images [20–22]. Our group has previously reported on the
stability and visibility of BioXmark throughout the treatment
course of patients with non-small cell lung cancer (NSCLC) referred
for definitive RT [23]. In this short communication we report on
safety, marker visibility and stability during the injection proce-
dure and through a follow-up period of three years.
Table 1
Baseline patient characteristics.
Patient characteristics n
Gender
Male/Female 9/6
Age
Median (range) [years] 64 (53–78)
WHO performance status
0/1 6/9
Charlson comorbidity score
Median (range) 6 (4–7)
Clinical stage
IIIA/IIIB/IVa 5/9/1
Pathology
Squamous cell carcinoma 6
Adenocarcinoma 7
Other 2
Location of primary tumour
Right upper lobe 6
Right lower lobe 4
Left upper lobe 1
Left lower lobe 3
Central 1
Gross tumour volume
Median (range) [cm3] 136 (30–522)
a M1a, contralateral lung metastasis diagnosed at
planning.
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The study was an open label, clinical feasibility study. It was
approved by the local ethics committee (H-1-2013-133), the Dan-
ish National Board of Health (Application #2013113675) and was
registered on clinicaltrials.gov (NCT02447900).
Patients with NSCLC referred for concurrent chemo-
radiotherapy (66 Gy in 33 fractions) with no iodine allergy were
eligible for inclusion.
The marker injection was performed within a two-week win-
dow between the first induction cycle of chemotherapy and the
RT planning procedure. Two experienced pulmonologists per-
formed the marker injections as an outpatient procedure. Marker
injection sites were primary tumour (if possible) and endoscopi-
cally reachable pathologic mediastinal lymphnodes. During seda-
tion, the marker was injected using a 22G needle using either a
conventional video-bronchoscope, an endobronchial ultrasound
bronchoscope (EBUS) or an oesophageal endoscopic ultrasound
(EUS) device. Marker injection was monitored with real-time ultra-
sound guidance (all but one patients) or C-arm fluoroscopy. Dop-
pler ultrasound was used to minimize the risk of endovascular
marker injection. The injection volume was limited per protocol
to a maximum of 0.5 ml per site and four sites per patient. Sedation
and post-procedure monitoring were performed per local guideli-
nes for interventional endoscopic procedures.
Image acquisition for RT treatment planning included a FDG
PET/Computed tomography (CT), a respiratory correlated 4DCT,
and three consecutive CT scans in voluntary deep inspiration
breath-hold (DIBH). Intravenous contrast enhancement was used
in the FDG-PET/CT and in the 4DCT scans. All patients were
planned and treated with volumetric arc therapy technique
(VMAT) (Varian Medical System, Palo Alto, CA, USA) in either DIBH
or free breathing. Daily cone beam CT (CBCT) with registration on
the tumour was used for image guidance. Orthogonal 2D X-ray flu-
oroscopies were acquired after treatment fractions 2, 16 and 30 for
analysis of marker visibility.
Treatment and device related toxicity was registered at base-
line, halfway through- and at the end of the RT course using CTCAE
v. 4.0. After completion of treatment, all patients entered a follow-
up procedure, consisting of a diagnostic CT scan and a clinical eval-
uation every three months until 18 months and thereafter at six-
month intervals until five years of follow-up or death. In case of
progression, the follow-up interval was changed to fit with the
intervals of treatment. Measurement of marker volume and opac-
ity was performed on the planning CT, treatment CBCT and on
follow-up CT scans (3,6,9,12,18,24,36 months).Results
Fifteen patients were included in the study. Baseline patient
characteristics are shown in Table 1.
A total of 35 markers were injected in 15 patients, 11 into or
near the primary tumour (T) and 24 into the hilar or mediastinal
lymph nodes (N). Two marker injections into endobronchial
tumours were performed by visual guidance using a conventional
video-bronchoscope, the remaining injection procedures were per-
formed using EUS and EBUS endoscopes with real-time monitoring
of the injected volume (Fig. 1). One to four markers were injected
per patient. Lymph node markers were injected into PET-positive
mediastinal and hilar lymph nodes. For details see Rydhög et al.
[23].
Two patients did not receive RT. One patient was diagnosed
with multiple lung metastases on the planning PET/CT. Another
patient died between marker injection and RT start. A subsequent
autopsy including a post mortem CT-scan found the injected mar-ker in situ at the injection site. The autopsy report concluded acute
heart failure as the cause of death.
One marker-related event was registered in relation to the
injection procedure: patient 5 had a marker placed in an endo-
bronchial tumour using a video-bronchoscope. The marker did
not appear on the planning CT images, but a new and slightly
PET positive, hyperdense area was observed in the phrenico-
costal sinus of the ipsilateral lung. It was suspected that the marker
was accidently injected into the pleural cavity. The patient had no
symptoms during or after the procedure. To minimise the risk of
endovascular injection all subsequent injections were monitored
with Doppler ultrasound.
A technical aspect was reported during marker injection in the
second patient. Contamination of the working channel with a
residual drop of marker liquid caused the needle to adhere to the
working channel damaging the fiberoptic part of the endoscope.
Procedures for needle loading were updated and no other equip-
ment related complications were reported.
No further complications were observed in relation to the injec-
tion procedure, during the RT period or in the follow-up period. A
total of 98 adverse events, including 53 serious adverse events
were reported during the study period. Apart from the events
described above, none were related to the marker.
Thirty-two markers (10 T and 22 N) were injected in the thir-
teen patients receiving RT. The two markers injected into endo-
bronchial tumours by visual guidance did not appear on the
planning CT images. One T marker was too dispersed to act as a
fiducial marker. The markers (0.1–0.2 ml) injected into lymph
nodes were generally more well-defined compared to the larger
volume markers (0.20–0.30 mL) injected in the primary tumours
which adopted a more complex 3D shape. The 29 markers suitable
as fiducial markers remained visible throughout the RT course. The
injected markers displayed high Hounsfield Unit (HU) values with
a mean >900 on CT and CBCT images, and all marker sizes were
identifiable on fluoroscopy [23] and CBCT (Figs. 1 and 2) through-
out the full treatment course.
Median follow-up time was 34 months (0–38 months) at data
lock December 31, 2017. In all follow-up scans performed the
markers remained visible and in-situ relative to the implantation
site by manual assessment. (Fig. 2). The measurements of marker
Fig. 1. Example of ultrasound guided injection (EBUS probe) of liquid marker in a pig (A). Arrow 1 marks the needle tip and arrow 2 the liquid marker (A). B–D) Images of a
patient with liquid markers injected into lymph node stations 4 L and 10 L: Anterior-posterior fluoroscopy projection with the markers encircled (B), axial plane from a
computed tomography (C) and a cone beam computed tomography (D).
Fig. 2. Example of liquid fiducial marker (300 mL) implanted in a primary tumour. Axial images of the planning CT (left), the CBCT at fraction 32 (middle) and follow-up CT
21 months after treatment (right).
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size of approximately 35% after 9 months, followed by a steady
state with no significant size reduction between the 12 and
36 month scans. Marker opacity was constant during the treat-
ment and follow up period (Fig. 3).Discussion
Our study is the first to examine the BioXmark liquid fiducial
marker long term stability and safety during follow-up in a human
population. We found no serious adverse events in relation to the
injection procedure or during treatment and follow-up.An advantage of the liquid fiducial marker is that it can be
injected with standard endoscopic (EUS/EBUS) equipment with
22–25 gauge needles compared to the 18–19 gauge needles used
for placement of most solid metal fiducial markers [6,11]. The liq-
uid formulation also allows for the placement of several markers in
one session without needing to ‘‘reload” the endoscopy needle
between each implantation as is most often the case with solid
metal markers [24]. The size of the liquid fiducial marker can be
customised by varying the injected volume. Preclinical studies,
where the marker was injected into phantoms, showed that a vol-
ume of as little as 10 ll was sufficient for the marker to appear vis-
ible in the CBCT images (data not published). However, a larger
volume is needed for the marker to appear visible on the 2D kV/
Fig. 3. Normalized values of marker volume (left) and –contrast (right) during follow up, showing a steady state in marker volume after 9 months and stable marker contrast
values throughout the period.
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the injected markers remained constant throughout the RT course,
as did the volume of the marker [23].
The low pneumothorax risk in our study agrees with previous
studies where fiducial markers were implanted in lung tissue or
mediastinum using endoscopic techniques [8,13,15,25,26]. Three
of 32 (9%) markers in patients receiving RT were lost or not suitable
as fiducial markers at the planning CT images. In comparison, in
studies of endoscopically implanted solid metal fiducial markers,
the marker loss varies from 0–2% (coil shaped markers) to 25–
53% (linear markers) and 21% (sphere-shaped markers) [25–28].
While there are multiple studies of solid metal fiducial markers
in RT of lung cancer patients [4–15], the experience with liquid
fiducial markers in this group of patients is limited. Two other liq-
uid based fiducial markers have been clinically tested: TraceIT
(Augmenix, Waltham, MA) and Lipiodol (Lipiodol Ultra-Fluide,
Guerbet Laboratorie, Villepinte, France). TraceIT is a hydrogel-
based radiopaque marker developed for use in surgery and RT
[16]. Studies with TraceIT in human cadavers and patients with
oesophageal cancer demonstrated radio-opacity of around 300
HU and visibility in CT, MRI and ultrasound images, but not in
2D kV X-ray images [16,17]. Lipiodol is an oil-based contrast agent
and has been reported used in RT of four patients with lung cancer
[18] Lipiodol deposits were injected via EBUS and electromagnetic
navigational bronchoscopy (ENB) techniques and were visible on
ultrasound, 2D kV X-ray and CT images. Three of the four patients
received radiotherapy, but no data on the marker performance
during the RT course was reported.
As the present study was a first in man study, a detailed analysis
on marker degradation during follow up was undertaken. From
preclinical studies, the time until full degradation was estimated
at up to three years. The measurements showed degradation of
the marker until approximately 9 months, after which a steady
state with no degradation was seen. In the preclininical animal
studies, histology examinations after 28, 90 and 365 days revealed
the formation of a thin fibrous capsule around the marker, possibly
slowing down the hydrolysis reaction responsible for the break-
down of the marker. The HU values of the marker were constant
throughout the study period, confirming degradation happens on
the marker surface rather than being a homogenous degradation.
Since marker positional stability is only crucial during treat-
ment and no post treatment marker related complications has pre-
viously been reported in lung cancer patients, information on
possible marker migration in this group of patients is limited. In
the lipiodol study follow up CT images showed marker material
present at the implantation site after up to 8 months post RT[18]. Another study where solid metal fiducial markers was
implanted in 10 lung cancer patients, showed no marker migration
in follow-up CT images up to 18 months post-treatment [29]. In
the present study, no marker migration relative to the injection site
was found in CT images up to 36 months after end of treatment.
In conclusion, the liquid fiducial marker in this study
(BioXmark) was safe to endoscopically inject into primary tumours
and lymph nodes in patients with locally advanced NSCLC and pro-
vided adequate visibility and stability when acting as fiducial
markers for image guided radiotherapy. The marker was partially
degraded during a three year follow up. No post-RT marker migra-
tion or complications were found.Conflicts of interest
None.
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